Inhaled Insulin for Pediatric Type 1 Diabetes: Analyzing the INHALE-1 Trial Results and Clinical Implications
Posted inDiabetes & Endocrinology news Pediatrics

Inhaled Insulin for Pediatric Type 1 Diabetes: Analyzing the INHALE-1 Trial Results and Clinical Implications

The INHALE-1 trial evaluated inhaled technosphere insulin in children. While it narrowly missed the primary HbA1c noninferiority margin, the study demonstrated improved patient satisfaction, reduced weight gain, and a favorable safety profile, suggesting its potential as a needle-free alternative for select pediatric patients.
Dietary Inflammatory and Insulinemic Potentials Drive Type 2 Diabetes Progression Following Gestational Diabetes: Insights from the Nurses’ Health Study II
Posted inDiabetes & Endocrinology news

Dietary Inflammatory and Insulinemic Potentials Drive Type 2 Diabetes Progression Following Gestational Diabetes: Insights from the Nurses’ Health Study II

A prospective study of 4,318 women reveals that dietary patterns promoting inflammation and hyperinsulinemia significantly elevate the risk of progressing from gestational diabetes to type 2 diabetes, with BMI serving as a primary mediator of this metabolic transition.
Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
Posted inDiabetes & Endocrinology news Oncology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immunotherapy increasing risk and concurrent chemotherapy appearing protective.
Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP
Posted inCardiology Diabetes & Endocrinology news

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated or stable/decreasing NT-proBNP, supporting a biomarker-guided approach to prevention.
Rethinking Radioactive Iodine Therapy for T1-T2 Papillary Thyroid Carcinoma with Lymph Node Metastasis: A Multicenter Analysis
Posted inDiabetes & Endocrinology news Oncology

Rethinking Radioactive Iodine Therapy for T1-T2 Papillary Thyroid Carcinoma with Lymph Node Metastasis: A Multicenter Analysis

A multicenter study in China demonstrates that radioactive iodine therapy may not significantly improve structural or biochemical response rates in T1-T2 stage papillary thyroid carcinoma with lymph node metastasis, highlighting the lymph node ratio as a more critical predictor of recurrence.
Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease
Posted inCardiology Diabetes & Endocrinology news

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesity, highlighting benefits beyond traditional major adverse cardiovascular events.